ADIPOQ and Insulin resistance: A recent clinical trial revealed pioglitazone plus vildagliptin treatment improved both adiponectin and resistin levels and might effective in preserving beta-cell function, and in reducing insulin resistance and inflammatory state parameters in subjects with poorly controlled T2DM [74].